First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials
In the ITT population, we found no differences in OS between amivantamab-lazertinib and osimertinib-chemotherapy, despite a slightly higher PFS of the latter. Osimertinib-chemotherapy could be more effective in patients with CNS metastases, without liver metastases, and EGFR L858R mutation, however we could not compare OS in these subgroups. Due to the indirect nature of the comparison and the limitation of the methods our results are not definitive, but rather hypothesis-generating. Other factors must be considered in the choice of the treatment, including patient's characteristics, the safety profile of the combinations, and center's facilities and expertise.
Authors
- Federico Cappuzzo (ORCID: https://orcid.org/0000-0002-6295-6767)
- Gabriele Minuti (ORCID: https://orcid.org/0000-0003-2363-0446)
- Mattia Alberto Di Civita (ORCID: https://orcid.org/0009-0009-3013-2622)
- E. Bengala (ORCID: https://orcid.org/0009-0005-8721-809X)
- Arianna Sabatini
- Fabio Ciurluini
- Andrea Torchia (ORCID: https://orcid.org/0000-0002-4020-6893)
- Lorenza Maria Landi (ORCID: https://orcid.org/0000-0003-2604-6595)
- M. Giammaruco
- Alain Gelibter (ORCID: https://orcid.org/0000-0002-7832-5281)
- Anastasia Laudisi
- Daniele Santini
- Daniele Marinelli
Institutions
- Policlinico Umberto I (IT)
- National Cancer Institute (MY)
- Istituti Fisioterapici Ospitalieri (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108845
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00